Outset Medical (OM) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue was $29.5M and full-year revenue reached $113.7M, both exceeding updated guidance but below the original plan.

• Recurring revenue and gross margin both grew sequentially, with cost-down measures reducing operating expenses.

• Strengthened balance sheet with $172.7M equity financing and reduced debt from $200M to $100M, extending maturity to 2030.

• Closed FDA warning letter from July 2023, following a successful inspection with no 483 observations.

• Net loss narrowed to $19.3M non-GAAP in Q4 and $93.4M for 2024, with significant year-over-year improvement.

Financial highlights

• Q4 revenue grew 3% sequentially but declined 3% year-over-year; full-year revenue declined 13% from 2023.

• Recurring revenue reached $23.7M in Q4, up 13% sequentially and 17% year-over-year; full-year recurring revenue was $83.9M, up 21%.

• Q4 gross margin was 37.6% non-GAAP (36.5% GAAP), up 119 bps sequentially and nearly 11 percentage points year-over-year.

• Operating expenses in Q4 were $26.6M non-GAAP, down 27% year-over-year; full-year non-GAAP operating expenses were $119.3M.

• Ended Q4 with $162M in cash and equivalents; post-financing, cash position is approximately $210M.

Outlook and guidance

• 2025 revenue expected between $115M–$125M, with installed base and recurring revenue both targeted to grow ~10%.

• Gross margin for 2025 projected in the high 30% range, with potential to exceed 40% by Q4, excluding under-absorption impacts.

• Operating expenses for 2025 anticipated at ~$90M, with cash usage under $50M, less than half of 2024.

• No expected impact from proposed Mexico tariffs due to product exemptions and inventory positioning.